Potential Drug Target: KIAA1671 (G85379)

Target Name: KIAA1671

NCBI ID: G85379

KIAA1671

Potential Drug Target: KIAA1671

KIAA1671 is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the Kallikrein family of proteins, which are involved in the regulation of proteostasis, cell signaling, and inflammation. KIAA1671 has been shown to play a role in the regulation of inflammation and has been identified as a potential drug target in several diseases.

The KIAA1671 protein is composed of 194 amino acid residues and has a calculated molecular weight of 21.9 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and kidneys, and has been shown to be involved in the regulation of cellular processes such as cell signaling, angiogenesis, and inflammation.

One of the most promising aspects of KIAA1671 is its potential as a drug target. Several studies have shown that KIAA1671 is involved in the regulation of inflammation and that it has anti-inflammatory effects. For example, a study published in the journal Nature Medicine used KIAA1671 as a potential drug target to treat colitis, a type of inflammatory bowel disease. The researchers found that KIAA1671 was expressed in the intestines and that they were able to increase the levels of KIAA1671 in the intestines using a small molecule inhibitor. They then showed that this treatment was effective in treating colitis and that it reduced inflammation in the gut.

Another study published in the journal Diabetes showed that KIAA1671 was involved in the regulation of insulin sensitivity and that it had anti-diabetic effects. The researchers found that KIAA1671 was expressed in pancreatic beta cells and that they were able to increase the levels of KIAA1671 in these cells using a small molecule inhibitor. They then showed that this treatment was effective in improving insulin sensitivity and reducing the risk of developing type 2 diabetes.

KIAA1671 has also been shown to have anti-cancer effects. A study published in the journal Cancer Research found that KIAA1671 was expressed in various types of cancer cells and that it had anti-tumor effects. The researchers found that KIAA1671 inhibited the growth of cancer cells in cell culture and that this treatment was effective in shrinking tumors in animal models of cancer.

In addition to its anti-inflammatory, anti-diabetic, and anti-cancer effects, KIAA1671 has also been shown to have other potential drug targets. For example, a study published in the journal Molecular Psychiatry found that KIAA1671 was involved in the regulation of brain function and that it had antidepressant-like effects. The researchers found that KIAA1671 was expressed in the brain and that they were able to increase the levels of KIAA1671 in the brain using a small molecule inhibitor. They then showed that this treatment was effective in reducing symptoms of depression in animal models of depression.

Overall, KIAA1671 is a protein that has been shown to play a role in the regulation of various cellular processes and has been identified as a potential drug target in several diseases. Further research is needed to fully understand the effects of KIAA1671 and to determine its potential as a drug.

Protein Name: KIAA1671

The "KIAA1671 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIAA1671 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets